Kiek dividendų moka Sino Biopharmaceutical 2024?
Pagal paskutinę informaciją nuo lapkritis 2024, Sino Biopharmaceutical per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,08 CNY už akciją. Esant dabartiniam Sino Biopharmaceutical kursui 3,30 CNY, tai atitinka 2,42 % dividendų grąžą.
Dividendai mokami kartus per metus.
2,42 % Dividendo grąža | = | 0,08 CNY Dividendas | 3,30 CNY akcijų kaina |
|
Ar Sino Biopharmaceutical dividendai yra saugūs?
Sino Biopharmaceutical kasmet didina dividendus jau 2 metus.
Per pastaruosius 10 metus Sino Biopharmaceutical kasmet 18,369 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 17,601 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų didinimas bus 2,509%.
Sino Biopharmaceutical Aktienanalyse
Ką daro Sino Biopharmaceutical?
Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange.
The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry.
Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies.
Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market.
Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis.
Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing.
In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries. Sino Biopharmaceutical yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.